Skip to main content

Advertisement

SpringerLink
Log in

Secondary acute myeloid leukemia arising early after cyclophosphamide treatment

  • Case Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Acute myeloid leukemia (AML) can develop secondary to drug treatment. This phenomenon has been placed under the title “Therapy Related Acute Myeloid Leukemias and Myelodysplastic Syndromes” in the WHO classification of AML. Cyclophosphamide, which is used in various malignancies and rheumatological diseases, is an alkylating agent that plays a significant role in therapy related AML. Case description A patient treated with cyclophosphamide due to vasculitis, subsequently developed AML months after treatment. Conclusion Cyclophosphamide related AML is seen, in most cases, many years after exposure to the drug. The significance of this report lies in the fact that, to our knowledge, this is the most rapidly arising case of cyclophosphamide related AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  2. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9–21.

    Article  CAS  PubMed  Google Scholar 

  3. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica. 1999;84:937–45.

    CAS  PubMed  Google Scholar 

  4. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135–64.

    Article  PubMed  Google Scholar 

  5. Langford CA. Complications of cyclophosphamide therapy. Eur Arch Otorhinolaryngol. 1997;254:65–72.

    Article  CAS  PubMed  Google Scholar 

  6. National Institutes of Health, National Cancer Institute. Adult Acute Myeloid Leukemia Treatment (PDQ®), Alkylating agent-related acute myeloid leukemia and myelodysplastic syndromes (updated 28 March 2014; cited 23 Dec 2014) (about 12 screens). http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/healthprofessional/page2#Section_139.

  7. Mahr A, Heijl C, Le Guenno G. Faurschou M.ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27:45–56.

    Article  PubMed  Google Scholar 

  8. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener’s granulomatosis. J Rheumatol. 2008;35:11–3.

    CAS  PubMed  Google Scholar 

  9. Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987;8550:83–8.

    Article  Google Scholar 

  10. Smith RE. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer. 2003;4:273–9.

    Article  CAS  PubMed  Google Scholar 

  11. Safaa M. Ramadan, Tamer M Fouad, Valentina Summa, Syed KH Hasan, and Francesco Lo-Coco Acute myeloid leukemia developing in patients with autoimmune diseases. Haematologica. 2012;97:805–17.

    Article  Google Scholar 

  12. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52.

    Article  CAS  PubMed  Google Scholar 

  13. Mani D, Dorer RK, Aboulafia DM. Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma. 2009;9:316–9.

    Article  CAS  PubMed  Google Scholar 

  14. Park TS, Cheong JW, Song J, Choi JR. Therapy-related myelodysplastic syndrome with der(17)t(12;17)(q13;p13) as a new recurrent cytogenetic abnormality after treatment for chronic lymphocytic leukemia. Leuk Res. 2009;33:1001–4.

    Article  CAS  PubMed  Google Scholar 

  15. Bloomfield CD, Archer KJ, Mrózek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002;33:362–78.

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Ic Hastaliklari ABD, Gazi Universitesi Hastanesi, 06500, Besevler, Ankara, Turkey

    Hayretdin Koklu & Ramazan Civelek

  2. Division of Rheumatology, Department of Internal Medicine, Gazi University, Ankara, Turkey

    Abdurrahman Tufan

  3. Department of Pathology, Gazi University, Ankara, Turkey

    Nalan Akyurek

  4. Hacettepe University School of Medicine, Ankara, Turkey

    Yusuf Erkul

Authors
  1. Hayretdin Koklu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdurrahman Tufan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuf Erkul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nalan Akyurek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ramazan Civelek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hayretdin Koklu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koklu, H., Tufan, A., Erkul, Y. et al. Secondary acute myeloid leukemia arising early after cyclophosphamide treatment. Int J Clin Pharm 37, 289–291 (2015). https://doi.org/10.1007/s11096-015-0069-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-015-0069-4

Keywords

Search

Navigation